ACCEPTABILITY AND CLINICAL ACTIVITY OF 4 WEEKS TREATMENT BY S12024-2 IN 53 INPATIENTS WITH MODERATE TO SEVERE ALZHEIMERS-DISEASE

被引：0
|
作者：
ALLAIN, H
WEANES, K
NEUMAN, E
GANDON, JM
SALZMAN, V
MALBEZIN, M
GUEZ, D
机构：
[1] INST RECH INT SERVIER,F-92415 COURBEVOIE,FRANCE
[2] CDR LTD,READING R07 2BJ,BERKS,ENGLAND
[3] BIOTRIAL SA,DRUG EVALUAT & PHARMACOL RES,F-35000 RENNES,FRANCE
来源：
NEUROBIOLOGY OF AGING | 1994年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S136 / S137
页数：2
相关论文
共 50 条
  • [21] SUSTAINED CLINICAL REMISSION WITH VEDOLIZUMAB IN MODERATE-TO-SEVERE CROHN'S DISEASE: A GEMINI 2 POST HOC ANALYSIS OF WEEK 14 REMITTERS
    Hardi, Robert
    Bokemeyer, Bernd
    Sandborn, William J.
    Reinisch, Walter
    Shafran, Ira
    Stallmach, Andreas
    Ehehalt, Robert
    Geransar, Parnia
    Khalid, Javaria M.
    Tudor, David
    Schreiber, Stefan
    GASTROENTEROLOGY, 2018, 154 (06) : S389 - S389
  • [22] Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn's disease: A GEMINI 2 post hoc analysis of Week 14 remitters
    Hardi, R.
    Bokemeyer, B.
    Sandborn, W.
    Reinisch, W.
    Shafran, I.
    Stallmach, A.
    Ehehalt, R.
    Geransar, P.
    Khalid, J. M.
    Tudor, D.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S485 - S485
  • [23] Teduglutide, a Novel Mucosally Active Analog of Glucagon-Like Peptide-2 (GLP-2) for the Treatment of Moderate to Severe Crohn's Disease
    Buchman, Alan L.
    Katz, Seymour
    Fang, John C.
    Bernstein, Charles N.
    Abou-Assi, Souheil G.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (06) : 962 - 973
  • [24] CLINICAL AND NEUROPHYSIOLOGICAL EVALUATION OF 3 DOSES OF S120242 (50, 100, 200 MG OD) DURING REPEATED ORAL-ADMINISTRATION (7 DAYS) IN 12 OUT-PATIENTS WITH MILD-TO-MODERATE ALZHEIMERS-DISEASE
    DEROUESNE, C
    RENAULT, B
    GUEGUEN, B
    VANDERLINDEN, M
    LACOMBLEZ, L
    HOMEYER, P
    OUSS, L
    NEUMAN, E
    MALBEZIN, M
    BARRANDON, S
    GUEZ, D
    NEUROBIOLOGY OF AGING, 1994, 15 : S100 - S100
  • [25] RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn's Disease
    Bressler, B.
    Marshall, J. K.
    Atkinson, K.
    Sutcliffe, S.
    Pankovich, J.
    Jones, M.
    Kalyan, S.
    Gunn, H.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S029 - S030
  • [26] Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study
    Sandborn, W. J.
    Melmed, G. Y.
    McGovern, D. P. B.
    Loftus, E. V., Jr.
    Choi, J. M.
    Cho, J. H.
    Abraham, B.
    Gutierrez, A.
    Lichtenstein, G.
    Lee, S. D.
    Randall, C. W.
    Schwartz, D. A.
    Regueiro, M.
    Siegel, C. A.
    Spearman, M.
    Kosutic, G.
    Pierre-Louis, B.
    Coarse, J.
    Schreiber, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 330 - 342
  • [27] Infliximab treatment for ulcerative colitis: Clinical response, clinical remission, & mucosal healing in patients with moderate or severe disease in the active ulcerative colitis trials (ACT1 & ACT2)
    Present, Daniel H.
    Sandborn, William J.
    Rutgeerts, Paul J.
    Olson, Allan
    Diamond, Robert H.
    Johanns, Jewel R.
    Hegedus, Ronald
    Dabbous, Omar
    GASTROENTEROLOGY, 2008, 134 (04) : A493 - A493
  • [28] Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease The ESSENCE-2 Randomized Clinical Trial
    Akpek, Esen K.
    Wirta, David L.
    Downing, Johnathon E.
    Tauber, Joseph
    Sheppard, John D.
    Ciolino, Joseph B.
    Meides, Alice S.
    Kroesser, Sonja
    JAMA OPHTHALMOLOGY, 2023, 141 (05) : 459 - 466
  • [29] INTERIM ANALYSIS OF THE CLINICAL TRIAL INCYTOB (INTERFERON ALPHA-2A VERSUS CYCLOSPORINE A FOR THE TREATMENT OF SEVERE OCULAR BEHCET'S DISEASE)
    Deuter, Christoph
    Xenitidis, Theodoros
    Schoenfisch, Birgit
    Zierhut, Manfred
    Koetter, Ina
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S151 - S151
  • [30] Continued treatment with ixekizumab over 60 weeks provides sustained improvements in work productivity and activity levels: results from UNCOVER-2, a Phase 3 trial in patients with moderate-to-severe psoriasis
    Lynde, C.
    McBride, S.
    Stahle, M.
    Burge, R.
    Lin, C. -Y.
    Amato, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 69 - 70
12345